1. Subject living in the same household as that of any active COVID-19 positive individual at the time of enrolment, <br/ > 2. Have previously already received one or two doses of any COVID-19 vaccine except Covishield or Covaxin, <br/ > 3. Pregnant women, nursing women or women of childbearing potential who are or may not actively avoid pregnancy during the study period, <br/ > 4. Hospitalized patients, patients who need intensive care and/or require a ventilator to help them breathe, <br/ > 5. Subjects with body temperature of â?¥100.4°F ( >38.0°C) or symptoms of an acute illness at the time of screening or prior to vaccination, <br/ > 6. Subjects with history of Covid-19 infection after receiving primary vaccination. <br/ > 7. Subjects with known current or chronic history of any of the following conditions, likely to affect participation in the study: <br/ > a)Severe psychiatric conditions, <br/ > b)Any bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), <br/ > c)Allergic disease or reactions likely to be exacerbated by any component of the study vaccine (BEâ??s CORBEVAX vaccine), <br/ > 8. Individuals who report any medical condition, or as determined by a clinician, not suitable to receive protein based subunit COVID-19 vaccines, including but not limited to allergies to the active substance or other ingredients of the vaccine. <br/ > 9. Neurological illness, and any other serious chronic illness requiring hospital specialist supervision. <br/ > 10. Use of medication that impairs immune system in the last 6 months, except topical or inhaled steroids or short-term oral steroids (course lasting â?¤14 days). <br/ > 11. Receipt of prohibited concomitant medication that may jeopardize the safety of the participant or interpretation of the data. <br/ > 12. Planned use of any investigational or non-registered product other than the study vaccine during the trial period or 3 months prior to enrolment. <br/ > 13. Current or planned participation in prophylactic drug trials for the duration of the study. <br/ > 14. Individuals who are part of the study team or close family members of individuals conducting the study. <br/ > 15. Any medical condition that in the judgment of the investigator would make study participation unsafe. <br/ >

1. Subject living in the same household as that of any active COVID-19 positive individual at the time of enrolment, <br/ > 2. Have previously already received one or two doses of any COVID-19 vaccine except Covishield or Covaxin, <br/ > 3. Pregnant women, nursing women or women of childbearing potential who are or may not actively avoid pregnancy during the study period, <br/ > 4. Hospitalized patients, patients who need intensive care and/or require a ventilator to help them breathe, <br/ > 5. Subjects with body temperature of â?¥100.4°F ( >38.0°C) or symptoms of an acute illness at the time of screening or prior to vaccination, <br/ > 6. Subjects with history of Covid-19 infection after receiving primary vaccination. <br/ > 7. Subjects with known current or chronic history of any of the following conditions, likely to affect participation in the study: <br/ > a)Severe psychiatric conditions, <br/ > b)Any bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), <br/ > c)Allergic disease or reactions likely to be exacerbated by any component of the study vaccine (BEâ??s CORBEVAX vaccine), <br/ > 8. Individuals who report any medical condition, or as determined by a clinician, not suitable to receive protein based subunit COVID-19 vaccines, including but not limited to allergies to the active substance or other ingredients of the vaccine. <br/ > 9. Neurological illness, and any other serious chronic illness requiring hospital specialist supervision. <br/ > 10. Use of medication that impairs immune system in the last 6 months, except topical or inhaled steroids or short-term oral steroids (course lasting â?¤14 days). <br/ > 11. Receipt of prohibited concomitant medication that may jeopardize the safety of the participant or interpretation of the data. <br/ > 12. Planned use of any investigational or non-registered product other than the study vaccine during the trial period or 3 months prior to enrolment. <br/ > 13. Current or planned participation in prophylactic drug trials for the duration of the study. <br/ > 14. Individuals who are part of the study team or close family members of individuals conducting the study. <br/ > 15. Any medical condition that in the judgment of the investigator would make study participation unsafe. <br/ >